Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 [fentanyl] for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2010
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 12 May 2009 Actual End Date (Jan 2009) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2008 EMEA has issued a positive opinion, recommending approval of Abstral for the treatment of cancer pain, according to ProStarkan media release.